Abstract
Our knowledge and understanding of the pharmacogenetic disease malignant hyperthermia (MH) has been significantly advanced through investigations of the porcine animal model. The distinction between “trigger” and “safe” anesthetics for MH-susceptible (MHS) human patients was originally based on the results of testing these drugs in the MHS pig [1,2]. The efficacy of dantrolene sodium for treating and preventing MH was discovered by Harrison [3] via experiments with MH pigs. Subsequent to its discovery in pigs, MHS was reported to occur in other species including the dog [4], cat [5], and horse [6]. Because MH in man represents a spectrum of susceptibility [7] and is genetically heterogenous [8], thorough investigations of MH among different animal species may provide important genetic and epigenetic information that will further advance our understanding of MH in man. In this chapter, I attempt to document the current state of knowledge regarding MH in dogs, focusing on the interesting genetic and phenotypic differences between MH in dogs and in pigs and how understanding the basis for these differences may have an impact on our understanding of MH in man.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hall LW, Trim CM, Woolf N (1972) Further studies of porcine malignant hyperthermia. Br Med J 2: 145–148
Harrison GG, Saunders SJ, Biebuyck JF, Hickman R, Dent DM, Weaver V, Terblanche J (1969) Anaesthetic-induced malignant hyperpyrexia and a method for its prediction. Br J Anaesth 41: 844–854
Harrison GG (1975) Control of the malignant hyperpyretic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 47: 62–65
Short CE, Paddleford RR (1973) Malignant hyperthermia in the dog. Anesthesiology 39: 462–463
De Jong RH, Hoarner JE, Amory DW (1974) Malignant hyperthermia in the cat. Anesthesiology 41: 608–609
McClure JJ (1975) Malignant hyperthermia in the horse. Minn Vet 15: 11–12
Nelson TE, Flewellen EH, Gloyna DF (1983) Spectrum of susceptibility of malignant hyperthermia: diagnostic dilemma. Anesth Analg 62: 545–552
Levitt RC, Nouri N, Jedlicka AE, McKusick VA, Marks AR, Shuttack JG, Fletcher JE, Rosenberg H, Meyers DA (1991) Evidence for genetic heterogeneity in malignant hyperthermia. Genomics 11: 543–547
Bagshaw RJ, Cox RH, Knight DH, et al (1978) Malignant hyperthermia in a greyhound.
Kirmayer AH, Klide AM, Purvance JE (1984) Malignant hyperthermia in a dog: case report and review of the syndrome. J Am Vet Med Assoc 185: 978–982
Leary SL, Anderson LC, Manning PJ, et al (1983) Recurrent malignant hyperthermia in a greyhound. J Am Vet Med Assoc 182: 521–522
O’Brien PI, Cribb PH, White RJ, et al (1983) Canine malignant hyperthermia: diagnosis of susceptibility in a breeding colony. Can Vet J 24: 172–177
Rand JS, O’Brien P (1987) Exercise-induced malignant hyperthermia in an English springer spaniel. J Am Vet Med Assoc 190: 1013–1014
Nelson TE (1991) Malignant hyperthermia in dogs. J Am Vet Med Assoc 198: 989–994
Britt BA, Kalow W (1970) Malignant hyperthermia: a statistical review. Can Anaesth Soc J 17: 293–315
Nelson TE (1993) Pharmacogenetics and malignant hyperthermia. Anaesth Pharmacol Rev 1: 362–376
Nelson TE (1990) Porcine malignant hyperthermia: critical temperatures for in vivo and in vitro responses. Anesthesiology 73: 449–454
Nelson TE (1987) Skeletal muscle sarcoplasmic reticulum in the malignant hyperthermia syndrome. In: Britt BA (ed) Malignant hyperthermia. Nijhoff, Boston, pp 4378
Jenden DJ, Fairhurst AS (1969) The pharmacology of ryanodine. Pharmacol Rev 21: 124
Chu AM, Diaz-Munoz M, Hawkes MJ, Brush K, Hamilton SL (1990) Ryanodine as a probe for the functional state of the skeletal muscle sarcoplasmic reticulum calcium release channel. Mol Pharmacol 37: 735–741
Fujii J, Otsu K, Zarzato S, de Leon VK, Khanna JE, Weiler JE, O’Brien PJ, MacLennan DH (1991) Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253: 448–451
MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodis W, Britt BA, Worton RG (1990) Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 343: 559–561
McPherson PS, Campbell KP (1993) The ryanodine receptor/calcium release channel. J Biol Chem 268: 13675–13678
Nelson TE, Sweo T (1988) Ca“ uptake and Ca” release by skeletal muscle sarcoplasmic reticulum: differing sensitivity to inhalational anesthetics. Anesthesiology 69: 571577
Louis CF, Zualkernan K, Roghair T, Mickelson JR (1992) The effects of volatile anesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology 77: 114–125
Nelson TE, Nelson KE (1990) Intra-and extrahumenal sarcoplasmic reticulum regulatory sites for Ca“-induced Ca” release. FEBS Lett 263: 292–294
Nelson TE (1983) Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia. J Clin Invest 72: 862–870
Nelson TE, Levin M, Volpe P (1991) Evidence for intraluminal Ca“ regulatory site defect in sarcoplasmic reticulum from malignant hyperthermia pig muscle. J Pharmacol Exp Ther 256: 645–649
MacLennan DH, Phillips MS (1992) Malignant hyperthermia. Science 256: 789–794
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Tokyo
About this paper
Cite this paper
Nelson, T.E. (1996). Malignant Hyperthermia in Dogs. In: Morio, M., Kikuchi, H., Yuge, O. (eds) Malignant Hyperthermia. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68346-9_23
Download citation
DOI: https://doi.org/10.1007/978-4-431-68346-9_23
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-68348-3
Online ISBN: 978-4-431-68346-9
eBook Packages: Springer Book Archive